LifeStance (LFST) Health Group announced that pursuant to a shelf registration statement filed with the SEC, certain stockholders of the company intend to offer 25M shares of LifeStance’s common stock. The company is not selling any shares of Common Stock in the offering and will not receive any proceeds from the offering. In addition, the company has authorized the concurrent purchase from the underwriter of 7M shares of common stock, subject to the completion of the offering. J.P. Morgan is acting as the underwriter for the offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST:
- LifeStance price target raised to $10 from $8 at BMO Capital
- LifeStance Health: Strong Q4 Beat, Productivity Gains, and Differentiated Clicks-and-Mortar Model Underscore Undervalued Buy Thesis
- LifeStance Health Guides 2026 Growth, Announces Buyback Program
- LifeStance reports Q4 EPS 2c, consensus 5c
- LifeStance sees FY26 revenue $1.615B-$1.655B, consensus $1.62B.